CN106459066B - 治疗睡眠过度的方法 - Google Patents

治疗睡眠过度的方法 Download PDF

Info

Publication number
CN106459066B
CN106459066B CN201580031853.4A CN201580031853A CN106459066B CN 106459066 B CN106459066 B CN 106459066B CN 201580031853 A CN201580031853 A CN 201580031853A CN 106459066 B CN106459066 B CN 106459066B
Authority
CN
China
Prior art keywords
ptz
certain embodiments
subject
administered
hypersomnia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580031853.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459066A (zh
Inventor
林登·利恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BALANCE THERAPEUTICS Inc
Original Assignee
BALANCE THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BALANCE THERAPEUTICS Inc filed Critical BALANCE THERAPEUTICS Inc
Publication of CN106459066A publication Critical patent/CN106459066A/zh
Application granted granted Critical
Publication of CN106459066B publication Critical patent/CN106459066B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580031853.4A 2014-04-15 2015-04-14 治疗睡眠过度的方法 Expired - Fee Related CN106459066B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979918P 2014-04-15 2014-04-15
US61/979,918 2014-04-15
PCT/US2015/025696 WO2015160766A1 (en) 2014-04-15 2015-04-14 Methods for treating hypersomnia

Publications (2)

Publication Number Publication Date
CN106459066A CN106459066A (zh) 2017-02-22
CN106459066B true CN106459066B (zh) 2020-07-07

Family

ID=54324484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580031853.4A Expired - Fee Related CN106459066B (zh) 2014-04-15 2015-04-14 治疗睡眠过度的方法

Country Status (12)

Country Link
US (3) US10688103B2 (https=)
EP (1) EP3131904A4 (https=)
JP (2) JP6672264B2 (https=)
KR (1) KR20170005415A (https=)
CN (1) CN106459066B (https=)
AU (2) AU2015247829B2 (https=)
CA (1) CA2945705A1 (https=)
EA (1) EA201692061A1 (https=)
IL (1) IL248255A0 (https=)
MX (1) MX2016013340A (https=)
WO (1) WO2015160766A1 (https=)
ZA (1) ZA201607068B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
WO2018209119A1 (en) * 2017-05-10 2018-11-15 Emory University Treatment of conditions associated with myotonic dystrophy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20110028418A1 (en) * 2008-03-12 2011-02-03 Emory University Use of gabba receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
US20120157445A1 (en) * 2010-12-17 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Cognitive Function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137746A (ja) * 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
US20110038850A1 (en) 2007-01-05 2011-02-17 Didier Bagnol G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders
EP2678320B1 (en) 2011-02-23 2018-09-19 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
CA2835018C (en) 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028418A1 (en) * 2008-03-12 2011-02-03 Emory University Use of gabba receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20120157445A1 (en) * 2010-12-17 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Cognitive Function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L"EEG DANS LA NARCOLEPSIE-CATAPLEXIE;BEDRICH ROTH et al.;《ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY》;19641231;第16卷;第170-190页，第176页右栏第1-3段 *

Also Published As

Publication number Publication date
EP3131904A1 (en) 2017-02-22
EA201692061A1 (ru) 2017-03-31
JP6672264B2 (ja) 2020-03-25
JP2020105200A (ja) 2020-07-09
IL248255A0 (en) 2016-11-30
CA2945705A1 (en) 2015-10-22
AU2019268190A1 (en) 2019-12-12
KR20170005415A (ko) 2017-01-13
CN106459066A (zh) 2017-02-22
ZA201607068B (en) 2023-01-25
JP2017511386A (ja) 2017-04-20
EP3131904A4 (en) 2017-11-22
WO2015160766A1 (en) 2015-10-22
US20200360398A1 (en) 2020-11-19
MX2016013340A (es) 2017-02-09
AU2015247829A1 (en) 2016-10-27
AU2015247829B2 (en) 2019-12-05
US10688103B2 (en) 2020-06-23
US20230115839A1 (en) 2023-04-13
US20180169107A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
KR102682159B1 (ko) 수면 무호흡을 치료하기 위한 방법 및 조성물
EP2962686B1 (en) Dosage form containing oxycodone and naloxone
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
CN113692277B (zh) 用于治疗睡眠呼吸暂停的方法和组合物
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
JP2009517393A (ja) 不安症の治療方法
KR20210007948A (ko) 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도
US20230115839A1 (en) Methods For Treating Hypersomnia
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
HK40120547A (zh) 用於治疗睡眠呼吸暂停的方法和组合物
HK40065333B (en) Methods and compositions for treating sleep apnea
EA048116B1 (ru) Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
HK40013951A (en) Methods and compositions for treating sleep apnea
HK1219669A1 (en) Dosage form containing oxycodone and naloxone
HK1111604B (en) Dosage form containing oxycodone and naloxone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200707

Termination date: 20210414

CF01 Termination of patent right due to non-payment of annual fee